Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial

SCORE2 Investigator Group; Ingrid U. Scott; Paul C. VanVeldhuisen; Michael S. Ip; Barbara A. Blodi; Neal L. Oden; Michael Altaweel; Daniel M. Berinstein

doi:10.1001/jamaophthalmol.2017.6843

Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial

SCORE2 Investigator Group
, Ingrid U. Scott
, Paul C. VanVeldhuisen
, Michael S. Ip
, Barbara A. Blodi
, Neal L. Oden
, Michael Altaweel
, Daniel M. Berinstein

Loma Linda University

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	337-345
Number of pages	9
Journal	JAMA Ophthalmology
Volume	136
Issue number	4
DOIs	https://doi.org/10.1001/jamaophthalmol.2017.6843
State	Published - Apr 2018

ASJC Scopus Subject Areas

Ophthalmology

Keywords

Bevacizumab/administration & dosage
Drug Administration Schedule
Follow-Up Studies
Intravitreal Injections
Tomography, Optical Coherence
Humans
Macular Edema/diagnosis
Male
Treatment Outcome
Visual Acuity
Macula Lutea/pathology
Ranibizumab/administration & dosage
Recombinant Fusion Proteins/administration & dosage
Time Factors
Angiogenesis Inhibitors/administration & dosage
Female
Aged
Receptors, Vascular Endothelial Growth Factor/administration & dosage
Vascular Endothelial Growth Factor A/antagonists & inhibitors

Access to Document

10.1001/jamaophthalmol.2017.6843

OpenUrl availability

Full text

Cite this

SCORE2 Investigator Group, Scott, I. U., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., & Berinstein, D. M. (2018). Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmology, 136(4), 337-345. https://doi.org/10.1001/jamaophthalmol.2017.6843

Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial. / SCORE2 Investigator Group; Scott, Ingrid U.; VanVeldhuisen, Paul C. et al.
In: JAMA Ophthalmology, Vol. 136, No. 4, 04.2018, p. 337-345.

Research output: Contribution to journal › Article › peer-review

SCORE2 Investigator Group, Scott, IU, VanVeldhuisen, PC, Ip, MS, Blodi, BA, Oden, NL, Altaweel, M & Berinstein, DM 2018, 'Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial', JAMA Ophthalmology, vol. 136, no. 4, pp. 337-345. https://doi.org/10.1001/jamaophthalmol.2017.6843

SCORE2 Investigator Group, Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmology. 2018 Apr;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843

@article{fcca4a37d71e446ba6c4ffc4f856dbce,

title = "Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial",

keywords = "Bevacizumab/administration \& dosage, Drug Administration Schedule, Follow-Up Studies, Intravitreal Injections, Tomography, Optical Coherence, Humans, Macular Edema/diagnosis, Male, Treatment Outcome, Visual Acuity, Macula Lutea/pathology, Ranibizumab/administration \& dosage, Recombinant Fusion Proteins/administration \& dosage, Time Factors, Angiogenesis Inhibitors/administration \& dosage, Female, Aged, Receptors, Vascular Endothelial Growth Factor/administration \& dosage, Vascular Endothelial Growth Factor A/antagonists \& inhibitors",

author = "\{SCORE2 Investigator Group\} and Scott, \{Ingrid U.\} and VanVeldhuisen, \{Paul C.\} and Ip, \{Michael S.\} and Blodi, \{Barbara A.\} and Oden, \{Neal L.\} and Michael Altaweel and Berinstein, \{Daniel M.\} and Sangeeta Bhargava and Figueroa, \{Maria J.\} and Musch, \{David C.\} and Han, \{Dennis P.\} and Sadda, \{Srinivas R.\} and Williams, \{George A.\} and Stephen Wisniewski and Janelle Gaston and Lena Bradley and \{De Stefano\}, Jodi and Eileen Guan and Anne Hoehn and Alexa Irazabal and Sue Isman and Jacquie King and Radhika Kondapaka and Hamsa Kumar and Matt Lahut and Robert Lindblad and Neal Oden and Michael Patschak and Rothwell, \{Ro Shauna\} and Rosemary Smith and \{Van Dyke\}, Janet and Valerie Watson and Lauren Yesko and Amitha Domalpally and Susan Reed and Pam Vargo and Cynthia Reed and Prema Abraham and Beth Bement-Stump and Leah Callahan and Mindi Dockter and Kristi Livermont and Robert Nixon and Dan Parks and Nathan Steinle and Alison Thompson and Joseph Fan and Michael Rauser and William Kiernan and Clement Chan and Kakarla Chalam",

year = "2018",

month = apr,

doi = "10.1001/jamaophthalmol.2017.6843",

language = "English",

volume = "136",

pages = "337--345",

journal = "JAMA Ophthalmology",

issn = "2168-6165",

number = "4",

}

TY - JOUR

T1 - Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications

T2 - Secondary outcomes from the SCORE2 randomized clinical trial

AU - SCORE2 Investigator Group

AU - Scott, Ingrid U.

AU - VanVeldhuisen, Paul C.

AU - Ip, Michael S.

AU - Blodi, Barbara A.

AU - Oden, Neal L.

AU - Altaweel, Michael

AU - Berinstein, Daniel M.

AU - Bhargava, Sangeeta

AU - Figueroa, Maria J.

AU - Musch, David C.

AU - Han, Dennis P.

AU - Sadda, Srinivas R.

AU - Williams, George A.

AU - Wisniewski, Stephen

AU - Gaston, Janelle

AU - Bradley, Lena

AU - De Stefano, Jodi

AU - Guan, Eileen

AU - Hoehn, Anne

AU - Irazabal, Alexa

AU - Isman, Sue

AU - King, Jacquie

AU - Kondapaka, Radhika

AU - Kumar, Hamsa

AU - Lahut, Matt

AU - Lindblad, Robert

AU - Oden, Neal

AU - Patschak, Michael

AU - Rothwell, Ro Shauna

AU - Smith, Rosemary

AU - Van Dyke, Janet

AU - Watson, Valerie

AU - Yesko, Lauren

AU - Domalpally, Amitha

AU - Reed, Susan

AU - Vargo, Pam

AU - Reed, Cynthia

AU - Abraham, Prema

AU - Bement-Stump, Beth

AU - Callahan, Leah

AU - Dockter, Mindi

AU - Livermont, Kristi

AU - Nixon, Robert

AU - Parks, Dan

AU - Steinle, Nathan

AU - Thompson, Alison

AU - Fan, Joseph

AU - Rauser, Michael

AU - Kiernan, William

AU - Chan, Clement

AU - Chalam, Kakarla

PY - 2018/4

Y1 - 2018/4

KW - Bevacizumab/administration & dosage

KW - Drug Administration Schedule

KW - Follow-Up Studies

KW - Intravitreal Injections

KW - Tomography, Optical Coherence

KW - Humans

KW - Macular Edema/diagnosis

KW - Male

KW - Treatment Outcome

KW - Visual Acuity

KW - Macula Lutea/pathology

KW - Ranibizumab/administration & dosage

KW - Recombinant Fusion Proteins/administration & dosage

KW - Time Factors

KW - Angiogenesis Inhibitors/administration & dosage

KW - Female

KW - Aged

KW - Receptors, Vascular Endothelial Growth Factor/administration & dosage

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

UR - https://www.scopus.com/pages/publications/85045540809

UR - https://www.scopus.com/pages/publications/85045540809#tab=citedBy

UR - https://www.mendeley.com/catalogue/b815101e-c7b9-3c0b-b814-87c05a6e7c0d/

U2 - 10.1001/jamaophthalmol.2017.6843

DO - 10.1001/jamaophthalmol.2017.6843

M3 - Article

C2 - 29476687

AN - SCOPUS:85045540809

SN - 2168-6165

VL - 136

SP - 337

EP - 345

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

IS - 4

ER -

Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinical trial

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this